---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-063740"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-09-28T20:47:56+00:00"
generated_at: "2026-10-12T13:37:21.725116+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics outlines Phase 1/2 ASCEND trial for CMP-002 in SYNGAP1-related disorder at Analyst Day

## Summary
- ASCEND is a Phase 1/2 randomized, double-blind, placebo-controlled MAD trial of intrathecal CMP-002 vs sham in patients aged 2 to <18 with genetically confirmed SYNGAP1-related disorder.
- Trial includes three MAD cohorts with at least eight participants each, 3:1 randomization, three doses over ~3 months, and a 28-day screening plus 4-week baseline.
- Sites in UK, Australia, and Argentina approved; EU under review; >11 sites across at least 9 countries; first patient dosing expected by end of 2026, topline H1 2028.
- Pipeline: preclinical SHANK3 program for Phelan-McDermid Syndrome, >45,000 US patients; development candidate expected in 2027; two additional early-stage CNS haploinsufficiency programs evaluated.
- Company believes CMP-002 dose levels in all three ASCEND cohorts are within expected therapeutic range based on preclinical PK/PD modeling.

## SEC filing metadata
- accession: 0001628280-26-063740
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-09-28T20:47:56+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/0001628280-26-063740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000162828026063740/camp-20260928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-063740
- JSON: https://secwatch.observer/filing/0001628280-26-063740.json
- Plain text: https://secwatch.observer/filing/0001628280-26-063740.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.